NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Any thoughts on the use of Decitabene?
It appears that, in relation to Glioblastoma it has only been researched with animal subjects by LL et al, though it is approved already for Acute Myeloid Leukemia. Could it be conceivably be employed in the existing DCVax phase 3 trial? Unlikely I suppose.

I'm a little concerned about the reported tumour 'swelling' that can apparently occur prior to tumour necrosis after L administration.
Wouldn't want this phenomenon to be mistaken for disease progression...

Re. the subgroupings, LL initially mentions four subgroupings, and that they subsequently adopted more meaningful titles used by other researchers, though only mentions three by name.
My interpretation of her presentation was that apart from the mesenchymal subgroup, the other subgroups (in mouse studies) benefited reliably and consistently from the use of Decitabene in addition to 'L' in animal studies, and the written report states systemic transfer (tail vein?) was superior to intra-cranial administration.

Decitabene apparently 'induces the expression of an immunogenic tumour rejection antigen NY-ESO-1.'

Would have been great if the video had included the subsequent Q and A session!